This program is supported by an independent education grant from Bayer. This online education program has been designed solely for healthcare professionals in the USA. The content is not available for healthcare professionals in any other country.

This accredited, free online session, designed for physicians and healthcare professionals involved in stroke prevention, will explore the latest evidence, trials and results relating to secondary prevention of stroke, including new insights on Factor XIa inhibition. Presented by leading experts Professor Jeffrey Saver & Professor Andrew Demchuk, the session will focus on new antithrombotic strategies and their role in reducing the global burden of secondary stroke.

Accreditation: 1.5 AMA PRA Category 1 Credits™

Session Highlights:

• Why Etiology Matters: Gain insights into the limitations of traditional antithrombotic treatments, including major bleeding risks, and also examine the latest evidence on the role of Factor XIa inhibition in this context.
• Latest in Secondary Stroke Prevention: Learn how to incorporate the most up-to-date evidence and guidelines into clinical practice, including the use of novel agents for secondary stroke prevention. Address common challenges such as hemorrhage risk, patient adherence, and effective follow-up care.
• Understanding the Global Stroke Burden: Explore the global and local impact of stroke on public health and healthcare systems. Discover the critical role of multidisciplinary teams (MDT) in reducing this burden and improving patient outcomes through coordinated, evidence-based approaches.

Presented by:

Professor Jeffrey Saver

Dr. Jeffrey Saver is a renowned neurologist at UCLA, where he serves as Medical Director of the UCLA Stroke Unit and Co-Director of the UCLA Stroke Center. He is also an Associate Professor of Neurology at UCLA's School of Medicine. Dr. Saver has authored over 80 original articles and contributed to numerous books. His research focuses on stroke prevention, acute treatment, and diagnosis. A Harvard graduate, he completed specialized training in neurology and stroke at prestigious institutions, including Brown University and the University of Iowa.

Professor Andrew Demchuk

Dr. Andrew Demchuk is a Professor in Clinical Neurosciences at the University of Calgary’s Cumming School of Medicine and a stroke neurologist with Alberta Health Services. He directs the Calgary Stroke Program and specializes in stroke research, particularly in vascular imaging to optimize patient selection for new treatments. Dr. Demchuk earned his medical degree from the University of Saskatchewan and completed a fellowship in cerebrovascular disease at the University of Texas-Houston. He has served on numerous stroke-related committees and received several prestigious awards.

Who is this course for

This online education program has been designed solely for healthcare professionals in the USA. The course provides continuing education for:

✅ Neurologists

✅ Critical care physicians

✅ Primary Care Physicians

✅ Nurses & Nurse Practitioners

✅ Pharmacists

✅ Other Health Professionals

Continuing Education Information

This continuing education activity is provided by AffinityCE and MedAll. This activity provides continuing education credit for physicians. A statement of participation is available to other attendees.

Faculty

Professor Jeffrey Saver, Professor Andrew Demchuk & Muzna Ahmed.

Disclosures

Andrew Demchuk

CME lectures for Bayer Pharmaceuticals, NovoNordisk & Astra Zeneca. Advisory board for Boehringer-Ingelheim/Roche, HLS Therapeutics/Pfizer & Servier. Research funding from Bayer Pharmaceuticals.

Intends to discuss non-FDA uses of drug products and/or devices and their unlabeled indications. This discussion relates to Factor XIa Inhibition in relation to stroke and will be disclosed to the audience when this discussion takes place.

Jeffrey Saver

Clinical trial steering committee member for Bayer.

Intends to discuss non-FDA uses of drug products and/or devices and their unlabeled indications. This discussion relates to Factor XIa Inhibition in relation to stroke and will be disclosed to the audience when this discussion takes place.

Muzna Ahmed

No relevant financial relationships with ineligible companies to disclose.

No unapproved product related discussions to disclose.

AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Relevant financial relationships were mitigated by the peer review of content by non-conflicted reviewers prior to the commencement of the program.

Activity Accreditation for Health Professions

UAN: 0829-9999-24-446-L01-P

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and Medall. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Continuing Nursing Education is provided for this program through the joint providership between MedAll and AffinityCE. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This live activity provides a maximum of 1.5 hours of continuing nursing education credit.

Criteria for Claiming CNE Credit: Participants must have registered and attended the entire program. Attendance is monitored online for participation in the entire activity.

Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Participation Costs

There is no cost to participate in this program.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.